Rose Mantel

发表

BTKC481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Novel SF3B1 in-frame deletions result in aberrant RNA splicing in CLL patients.

J. Byrd, M. Warmuth, A. Johnson, 2017, Blood advances.

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy.

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014, Blood.

The BTK Inhibitor ARQ 531 Targets Ibrutinib-Resistant CLL and Richter Transformation.

Lisa L. Smith, J. Byrd, F. Awan, 2018, Cancer discovery.

Targeting BTK through microRNA in chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, A. Bottoni, 2016, Blood.

LYMPHOID NEOPLASIA Targeting BTK through microRNA in chronic lymphocytic leukemia

Lisa L. Smith, J. Byrd, A. Bottoni, 2016 .

response to therapy distinct molecular characteristics and does not indicate a suboptimal Prolonged lymphocytosis during ibrutinib therapy is associated with

Jeffrey A Jones, Emanuela M. Ghia, Lisa L. Smith, 2014 .

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2015, JAMA oncology.

Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma

Lisa L. Smith, J. Byrd, R. Bundschuh, 2019, Clinical Cancer Research.

Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.

Lisa L. Smith, J. Byrd, A. Johnson, 2015, Blood.

The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia

Lisa L. Smith, R. Ulrich, J. Byrd, 2016, Clinical Cancer Research.

BTK C 481 S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia

M. Grever, J. Byrd, F. Awan, 2017 .

The Bruton's Tyrosine Kinase (BTK) Inhibitor ARQ 531 Effectively Inhibits Wild Type and C481S Mutant BTK and Is Superior to Ibrutinib in a Mouse Model of Chronic Lymphocytic Leukemia

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

REDX08608, a Novel, Potent and Selective, Reversible BTK Inhibitor with Efficacy and Equivalent Potency Against Wild-Type and Mutant C481S BTK

Victoria M Wright, Valentina Abet, J. Emmerich, 2016 .

the Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL

Jeffrey A Jones, Lisa L. Smith, M. Grever, 2016 .

Inhibitors of Bruton's Tyrosine Kinase Reduce Anti-Red Blood Cell Response in a Murine Model of Autoimmune Hemolytic Anemia

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .

Noncovalent inhibition of C481S Bruton tyrosine kinase by GDC-0853: a new treatment strategy for ibrutinib-resistant CLL.

Adam R. Johnson, Lisa L. Smith, J. Byrd, 2018, Blood.

Evaluation of the novel Bruton′s tyrosine kinase (BTK) inhibitor GDC-0853 in chronic lymphocytic leukemia (CLL) with wild type or C481S mutated BTK.

Lisa L. Smith, J. Byrd, A. Johnson, 2016 .